Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study

Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study

Abstract Background Nivolumab and cabozantinib are currently approved agents in metastatic renal cell carcinoma (mRCC) but there are no data available for patients progressing to both treatments. The aim of this study was to compare active therapeutic options and best supportive care (BSC) after pro...

Full description

Bibliographic Details
Main Authors:	Giandomenico Roviello, Elisabetta Gambale, Roberta Giorgione, Daniele Santini, Marco Stellato, Giuseppe Fornarini, Sara Elena Rebuzzi, Umberto Basso, Davide Bimbatti, Laura Doni, Gabriella Nesi, Melissa Bersanelli, Sebastiano Buti, Ugo De Giorgi, Luca Galli, Andrea Sbrana, Raffaele Conca, Claudia Carella, Emanuele Naglieri, Sandro Pignata, Giuseppe Procopio, Lorenzo Antonuzzo
Format:	Article
Language:	English
Published:	Wiley 2022-08-01
Series:	Cancer Medicine
Subjects:	fourth‐line therapy immune checkpoint inhibitors metastatic renal cell carcinoma targeted therapy tyrosine kinase inhibitors vascular endothelial growth factor receptor
Online Access:	https://doi.org/10.1002/cam4.4681

Similar Items

Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators
by: Marco Stellato, et al.
Published: (2021-08-01)

Adjuvant Therapy for Renal Cell Carcinoma: Hype or Hope?
by: Federica Cosso, et al.
Published: (2023-02-01)

Cabozantinib for HCC Treatment, From Clinical Back to Experimental Models
by: Shanshan Deng, et al.
Published: (2021-10-01)

Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib
by: Sara Elena Rebuzzi, et al.
Published: (2022-02-01)

Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study
by: Veronica Murianni, et al.
Published: (2024-02-01)

Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score
by: Giulia Mazzaschi, et al.
Published: (2023-07-01)

Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients
by: Elisa Giommoni, et al.
Published: (2021-08-01)

Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy
by: Grassi P, et al.
Published: (2016-07-01)

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential
by: Melissa Bersanelli, et al.
Published: (2017-10-01)

Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma
by: Francesco Tovoli, et al.
Published: (2021-06-01)

Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date
by: Bersanelli M, et al.
Published: (2018-09-01)

Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?
by: Lucia Musacchio, et al.
Published: (2020-06-01)

Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study
by: Sara Elena Rebuzzi, et al.
Published: (2023-04-01)

Cabozantinib in combination with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis
by: Jingyang Su, et al.
Published: (2024-04-01)

Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
by: Martina Catalano, et al.
Published: (2022-09-01)

Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade
by: Min Hwa Shin, et al.
Published: (2020-04-01)

The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study
by: Jeffrey Sum-Lung Wong, et al.
Published: (2021-04-01)

Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study)
by: Melissa Bersanelli, et al.
Published: (2021-07-01)

TARGETING THE EPIGENOME IN LUNG CANCER: EXPANDING APPROACHES TO EPIGENETIC THERAPY
by: Marko eJakopovic, et al.
Published: (2013-10-01)

Regression of Intracranial Meningiomas Following Treatment with Cabozantinib
by: Rupesh Kotecha, et al.
Published: (2021-04-01)

Real-world experience of cabozantinib in Asian patients with advanced renal cell carcinoma following treatment with VEGFR tyrosine kinase inhibitors and/or immune checkpoint inhibitors
by: Darren MC Poon, et al.
Published: (2023-06-01)

Systemic Therapy of Metastatic Melanoma: On the Road to Cure
by: Julian Steininger, et al.
Published: (2021-03-01)

Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors
by: Joline S. J. Lim, et al.
Published: (2017-08-01)

New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis
by: Elena Carmona-Rocha, et al.
Published: (2024-02-01)

Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)
by: Sara Elena Rebuzzi, et al.
Published: (2021-05-01)

Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma
by: Melissa Bersanelli, et al.
Published: (2023-01-01)

Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma
by: Sharon Del Vecchio, et al.
Published: (2018-10-01)

PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality—An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness
by: Patrycja Gralewska, et al.
Published: (2020-12-01)

Treatment of Advanced Melanoma: Past, Present and Future
by: Taku Fujimura, et al.
Published: (2020-09-01)

Cabozantinib: A narrative drug review
by: Vivek K Srigadha, et al.
Published: (2023-01-01)

Profile of Cabozantinib for the Treatment of Hepatocellular Carcinoma: Patient Selection and Special Considerations
by: Debaillon Vesque A, et al.
Published: (2020-06-01)

Effect of dabrafenib on melanoma cell lines harbouring the BRAF<sup><it>V600D/R</it></sup> mutations
by: Gentilcore Giusy, et al.
Published: (2013-01-01)

Advanced kidney carcinoma: decision paths and therapeutic perspectives
by: Valentina Da Prat, et al.
Published: (2014-09-01)

Unleashing the Power of Synthetic Lethality: Augmenting Treatment Efficacy through Synergistic Integration with Chemotherapy Drugs
by: Yajing Du, et al.
Published: (2023-10-01)

Current Peptide and Protein Candidates Challenging HIV Therapy beyond the Vaccine Era
by: Koollawat Chupradit, et al.
Published: (2017-09-01)

Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer
by: Gian Marco Leone, et al.
Published: (2023-04-01)

Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14)
by: Marco Maruzzo, et al.
Published: (2021-11-01)

Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib
by: Fabio Scirocchi, et al.
Published: (2021-10-01)

Molecularly Targeted Therapies for Gastric Cancer. State of the Art
by: Rossella Reddavid, et al.
Published: (2021-08-01)

Promising Treatment Options for Axial Spondyloarthritis: An Overview of Experimental Pharmacological Agents
by: Tahir H, et al.
Published: (2021-07-01)